孟鲁司特钠、西替利嗪联合丙卡特罗治疗小儿咳嗽变异性哮喘的临床效果  

Clinical Effect of Montelukast Sodium,Cetirizine and Procaterol in Treatment of Pediatric Cough Variant Asthma

作　　者：欧阳云翠 Ouyang Yuncui(Pediatrics Department,Hangzhou Gongshu District Shiqiao Street Community Health Service Center,Hangzhou 310015,Zhejiang Province,China)

机构地区：[1]杭州市拱墅区石桥街道社区卫生服务中心儿科,浙江杭州310015

出　　处：《中国社区医师》2024年第36期32-34,共3页Chinese Community Doctors

摘　　要：目的:探讨孟鲁司特钠、西替利嗪联合丙卡特罗治疗小儿咳嗽变异性哮喘(CVA)的临床效果。方法:选取杭州市拱墅区石桥街道社区卫生服务中心2022年1月—2023年12月收治的CVA患儿160例作为研究对象,采用随机数字表法将患儿分为对照组和观察组,各80例。对照组给予孟鲁司特钠治疗,观察组在对照组基础上给予西替利嗪联合丙卡特罗治疗。对比两组患儿临床症状评分、肺功能指标、不良反应发生率和复发情况。结果:治疗前,两组咳嗽、憋喘、哮鸣音评分比较,差异无统计学意义(P>0.05);治疗后,两组咳嗽、憋喘、哮鸣音评分均低于治疗前,且观察组低于对照组(P<0.05)。治疗前,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气流量峰值(PEF)比较,差异无统计学意义(P>0.05);治疗后,两组FEV1、FVC、PEF均高于治疗前,且观察组高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。观察组复发率低于对照组(P=0.037)。结论:孟鲁司特钠、西替利嗪联合丙卡特罗治疗小儿CVA的临床效果较好,能够缓解患儿的临床症状,改善肺功能,降低复发率,且安全性较高。Objective:To investigate the clinical effect of montelukast sodium,cetirizine and procaterol in the treatment of pediatric cough variant asthma(CVA).Methods:A total of 160 children with CVA admitted to Hangzhou Gongshu District Shiqiao Street Community Health Service Center from January 2022 to December 2023 were selected as the study subjects.The children were divided into control group and observation group according to random number table method,with 80 cases in each group.The control group was treated with montelukast sodium,and the observation group was treated with cetirizine and procaterol on the basis of control group.The clinical symptom scores,pulmonary function indexes,incidence of adverse reactions and recurrence were compared between the two groups.Results:Before treatment,there was no significant difference in the scores of cough,asthma and wheezing between the two groups(P>0.05).After treatment,the scores of cough,asthma and wheezing in the two groups were lower than those before treatment,and the scores in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference in forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC)and peak expiratory flow(PEF)between the two groups(P>0.05).After treatment,FEV1,FVC and PEF in the two groups were higher than those before treatment,and these indexes in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The recurrence rate in the observation group was lower than that in the control group(P=0.037).Conclusion:Montelukast sodium,cetirizine combined with procaterol in the treatment of pediatric CVA have good clinical effects,and can alleviate the clinical symptoms,improve lung function,reduce the recurrence rate,and have a high safety.

关 键 词：孟鲁司特钠 西替利嗪 丙卡特罗 小儿 咳嗽变异性哮喘 

分 类 号：R725.6[医药卫生—儿科]